Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy

Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy

Introduction: We reported increased spleen tyrosine kinase (SYK) expression in kidney biopsies of patients with IgA nephropathy (IgAN) and that inhibition of SYK reduces inflammatory cytokines production from IgA stimulated mesangial cells. Methods: This study was a double-blind, randomized, placebo...

Full description

Bibliographic Details
Main Authors: Frederick W.K. Tam, James Tumlin, Jonathan Barratt, Brad H. Rovin, Ian S.D. Roberts, Candice Roufosse, H. Terence Cook, Gurjeet Bhangal, Alison L. Brown, Martin Busch, Fayaz Dudhiya, Anne-Marie Duliege, Donald J. Fraser, Daniel P. Gale, Chiu-Ching Huang, Ping-Chin Lai, Meng Lee, Esteban S. Masuda, Stephen P. McAdoo, Alexander R. Rosenkranz, Claudia Sommerer, Gere Sunder-Plassmann, Cheuk-Chun Szeto, Sydney C.W. Tang, Don E. Williamson, Lisa Willcocks, Volker Vielhauer, Min Jeong Kim, Leslie Todd, Hany Zayed, Sandra Tong-Starksen, Richard Lafayette
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Kidney International Reports
Subjects:
glomerulonephritis
IgA nephropathy
inflammation
kidney
macrophage
signaling
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024923015176

Internet

http://www.sciencedirect.com/science/article/pii/S2468024923015176

Similar Items